Recombinant human platelet-derived growth factor: Biology and clinical applications
Recombinant human platelet-derived growth factor: Biology and clinical applications
复制标题
DOI：
10.2106/jbjs.g.01231
复制
发表时间：
2008-02-01
影响因子：
5.3
通讯作者：
Friedlaender, Gary E.
中科院分区：
文献类型：
--
作者：
Hollinger, Jeffrey O.;Hart, Charles E.;Friedlaender, Gary E.
骨骼重塑、骨折修复和骨移植融合的能力都是骨骼重塑周期的基本反映。这一过程的特点是成骨细胞和破骨细胞群的募集和分化，其细胞活动由生长因子和细胞因子的复杂系统协调和调节。负责修复骨活性的关键生物因素之一是血小板衍生生长因子（PDGF）。 PDGF 作为间充质细胞（包括成骨细胞）的化学引诱剂和有丝分裂原的有效刺激作用及其促进血管生成的能力，已在各种预测颌面部、脊柱和四肢骨骼以及软组织应用的临床前模型中得到证实。 PDGF 的生物学特性，包括其募集骨祖细胞的能力，使其特别适合解决骨质疏松症、糖尿病和吸烟等合并症引起的骨骼缺陷。使用重组人 PDGF (rhPDGF) 修复牙周缺损的临床成功和安全性已得到证实，美国食品和药物管理局 (FDA) 批准 rhPDGF 用于该适应症。美国和国际上正在进行的试点和关键试验将继续阐明 PDGF 在治疗具有挑战性的骨骼疾病方面的前景。
The abilities of bone to remodel, fractures to repair, and bone grafts to incorporate are all fundamental reflections of the bone remodeling cycle. This process is characterized by the recruitment and differentiation of osteoblastic and osteoclastic cell populations, whose cellular activities are coordinated and regulated by an elaborate system of growth factors and cytokines. One of the crucial biological factors responsible for reparative osseous activity is plate let-derived growth factor (PDGF). The potent stimulatory effects of PDGF as a chemoattractant and mitogen for mesenchymal cells (including osteogenic cells), along with its ability to promote angiogenesis, have been demonstrated in a variety of preclinical models predicting maxillofacial, spine and appendicular skeletal, and soft-tissue applications. The biological profile of PDGF, including its ability to recruit osteoprogenitor cells, makes it particularly suited to address the skeletal defects that are seen with comorbid conditions such as osteoporosis, diabetes, and the effects of smoking. The clinical success and safety that have been demonstrated with use of recombinant human PDGF (rhPDGF) in the repair of periodontal defects have led to U.S. Food and Drug Administration (FDA) approval of rhPDGF for this indication. Ongoing pilot and pivotal trials in the United States and internationally will continue to clarify the promising role of PDGF in the treatment of challenging skeletal disorders.